Three-month paliperidone palmitate - a new treatment option for schizophrenia

ABSTRACT

Introduction: Long-acting injectable antipsychotics (LAIAs) were introduced to improve treatment adherence and tolerability of oral formulations. After risperidone was introduced as the first long-acting injectable second-generation antipsychotic, during the last five years olanzapine pamoate, once-monthly paliperidone palmitate and once-monthly aripiprazole has also been marketed.

Areas covered: A three-month injection of paliperidone palmitate (3MPP) was introduced in the North-American market in 2015. It will be gradually available in the rest of the world in the coming years. The principal aim of this review is to evaluate its efficacy and tolerability and to discuss the possible role it may play.

Expert commentary: In the coming years an increase in the prescription rates of LAIAs is expected. 3MPP offers a substantially longer dosing interval than other options, which may be a potential advancement to reduce nonadherence. Future research and experiences will identify which subpopulation may obtain greater benefit from this new tool.

KEYWORDS:

• 3MPP
• three-month paliperidone palmitate
• paliperidone
• Invega Trinza
• Trevicta
• schizophrenia
• psychosis
• long-acting injectable antipsychotics
• adherence

Declaration of interest

M Bernardo has been a consultant for, received grant/research grant support and honoraria from, been on the speakers/advisory board of ABBiotics, Adamed, Almirall, AMGEN, Boehringer, Eli Lilly, Ferrer, Forum Pharmaceuticals, Gedeon, Hersill, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Roche, Servier and has obtained research funding from the Spanish Ministry of Health, the Spanish Ministry of Science and Education, the Spanish Ministry of Economy and Competiveness, Centro de Investigacion Biomedica en Red de Salud Mental (CIBERSAM), by the Government of Catalonia, Secretaria d’Universitats i Recerca del Department d’Economia i Coneixement, Institut d’Investigacions Biomediques August Pi i Sunyer (IDIBAPS), and the 7^th Framework Program of the European Union. M Bioque has been a consultant for, received honoraria from and/or been on the speakers/advisory board of Adamed, Ferrer, Janssen-Cilag, Lundbeck, Otsuka, and Pfizer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.